Entrada Therapeutics, Inc.
corporate_fare Company Profile
Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for TRDA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for TRDA spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Safety Committee Clears 15 mg/kg Dose, Entrada Advances DMD Study to Cohort 3
- Entrada Beats on Q3 Loss Per Share but Revenue Collapses 44% to $905K
- Entrada's ENTR-601-45 Shows Favorable Safety and Dystrophin Increase in DMD Cohort 1
- Entrada Q2 2026: $223M Cash, Runway to Q3 2027, and a Pipeline of Clinical Catalysts
- Entrada Reports Q2 2026 Results, Sets Near-Term Clinical Data Catalysts
Financial Snapshot
Short Interest & Short Volume
6.88 days to coverFINRA reported short interest of 2,807,309 shares in TRDA as of the October 30, 2026 settlement, a 14.2% decrease from the prior period — about 6.9 days to cover at its recent average daily volume. On November 20, 2026, 63.4% of TRDA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.